Antiviral Drugs - Saudi Arabia

Saudi Arabia

The Antiviral Drugs market in Saudi Arabia is expected to achieve a revenue of SAR US$224.80m in 2025.
This revenue is projected to grow at an annual growth rate (CAGR 2025-2029) of 1.24%, reaching a market volume of SAR US$236.20m by 2029.
In comparison to other countries, United States is anticipated to generate the highest revenue, amounting to US$31,150.00m in 2025.
Saudi Arabia's demand for antiviral drugs is on the rise due to the country's efforts to combat infectious diseases.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

Antiviral drugs have become increasingly popular in recent years due to the rise of viral infections around the world. Saudi Arabia is no exception to this trend, and the market for antiviral drugs in the country has been steadily growing.

Customer preferences: Customers in Saudi Arabia have shown a preference for antiviral drugs that are effective against a wide range of viruses. They also prefer drugs that have minimal side effects and are easy to administer. Additionally, there is a growing demand for antiviral drugs that can be used to treat emerging viruses, such as COVID-19.

Trends in the market: One of the key trends in the antiviral drugs market in Saudi Arabia is the increasing use of generic drugs. This is due to the fact that generic drugs are often more affordable than their branded counterparts, and they are becoming more widely available in the country. Another trend is the growing use of combination therapies, which involve the use of multiple antiviral drugs to treat a single infection. This approach has been shown to be more effective than using a single drug.

Local special circumstances: Saudi Arabia has a high prevalence of viral infections due to its location and climate. The country is also home to a large expatriate population, which can increase the risk of viral outbreaks. As a result, there is a growing need for effective antiviral drugs in the country.

Underlying macroeconomic factors: The Saudi Arabian government has been investing heavily in the healthcare sector in recent years. This has led to the development of new hospitals and clinics, as well as the expansion of existing facilities. This investment has also led to an increase in the availability of antiviral drugs in the country. Additionally, the country has a large and growing population, which is driving demand for healthcare services, including antiviral drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.